Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

卷:107

Review

Krinzinger, Helga¹  Hall, Charlotte L.²  Groom, Madeleine J.²  Ansari, Mohammed T.³  Banaschewski, Tobias⁴  Buitelaar, Jan K.^5,6  Carucci, Sara^7,8  Coghill, David^9,10,11,12  Danckaerts, Marina^13,14  Dittmann, Ralf W.¹⁵  Falissard, Bruno¹⁶  Garas, Peter¹⁷  Inglis, Sarah K.¹⁸  Kovshoff, Hanna¹⁹  Kochhar, Puja²  McCarthy, Suzanne²⁰  Nagy, Peter²¹  Neubert, Antje²²  Roberts, Samantha²³  Sayal, Kapil²  Sonuga-Barke, Edmund^24,25  Wong, Ian C. K.^26,27  Xia, Jun²⁸  Zuddas, Alessandro^7,8  Hollis, Chris^2,29,30  Konrad, Kerstin^1,31,32  Liddle, Elizabeth B.² 

[1] Univ Hosp, RWTH Aachen, Dept Child & Adolescent Psychiat Psychosomat & Ps, Sect Child Neuropsychol, Aachen, Germany

[2] Univ Nottingham, Inst Mental Hlth, Sch Med, Div Psychiat & Appl Psychol, Nottingham, England

[3] Univ Ottawa, Fac Med, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada

[4] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Dept Child & Adolescent Psychiat & Psychotherapy, Mannheim, Germany

[5] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Cognit Neurosci, Nijmegen, Netherlands

[6] Karakter Child & Adolescent Psychiat Univ Ctr, Nijmegen, Netherlands

[7] Univ Cagliari, Dept Biomed Sci, Child & Adolescent Neuropsychiat Unit, Cagliari, Italy

[8] Brotzu Hosp Trust, A Cao Pediat Hosp, Cagliari, Italy

[9] Univ Melbourne, Dept Paediat, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia

[10] Univ Melbourne, Dept Psychiat, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia

[11] Murdoch Childrens Res Inst, Melbourne, Vic, Australia

[12] Univ Dundee, Sch Med, Div Neurosci, Dundee, Scotland

[13] KU, Univ Psychiat Ctr, Dept Child & Adolescent Psychiat, Leuven, Belgium

[14] KU, Univ Psychiat Ctr, Dept Neurosci, Leuven, Belgium

[15] Heidelberg Univ, Cent Inst Mental Hlth, Dept Child & Adolescent Psychiat & Psychotherapy, Paediat Psychopharmacol,Med Fac Mannheim, Mannheim, Germany

[16] Univ Paris 05, Univ Paris Sud, AP HP, INSERM,U1178, Paris, France

[17] Semmelweis Univ, Karoly Racz Sch PhD Studies, Mental Hlth Sci Phd Sch, Budapest, Hungary

[18] Univ Dundee, Tayside Clin Trials Unit, Dundee, Scotland

[19] Univ Southampton, Sch Psychol, Southampton, Hants, England

[20] Univ Coll Cork, Sch Pharm, Cork, Ireland

[21] Vadaskert Child & Adolescent Psychiat Hosp, Budapest, Hungary

[22] Univ Hosp Erlangen, Dept Paediat & Adolescents Med, Erlangen, Germany

[23] Nottinghamshire Healthcare NHS Fdn Trust, Nottingham, England

[24] Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London, England

[25] Univ Ghent, Dept Expt Clin & Hlth Psychol, Ghent, Belgium

[26] UCL Sch Pharm, Res Dept Practice & Policy, Ctr Paediat Pharm Res, London, England

[27] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res,Hong Kong, Hong Kong, Peoples R China

[28] Univ Nottingham, Nottingham China Hlth Inst, Nottingham Ningbo GRADE Ctr, Ningbo, Zhejiang, Peoples R China

[29] Natl Inst Hlth Res NIHR MindTech MedTech Cooperat, Nottingham, England

[30] NIHR Nottingham Biomed Res Ctr, Nottingham, England

[31] Forschungszentrum Julich, JARA BRAIN Inst 2, Mol Neurosci & Neuroimaging, Aachen, Germany

[32] Rhein Westfal TH Aachen, Aachen, Germany

关键词: Long-term methylphenidate treatment;    ADHD;    Adverse neuropsychiatric events;    Mood;    Anxiety;    Suicidal ideation;    Bipolar;    Psychosis;    Substance use disorder;    Tics;    Seizures;    Sleep disorders;   

DOI  :  10.1016/j.neubiorev.2019.09.023

来源: Elsevier

【 摘 要 】

Methylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1 year) treatment in ADHD. We coded studies using a traffic light system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as Unclear. Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention.

【 授权许可】

Free